Search

Search Constraints

You searched for: Author/Creator Mackiewicz, A.

Search Results

1. 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. (September 2015)

2. 3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM). (September 2015)

4. HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy‐treated HIV/HCV‐co‐infected subjects. Issue 10 (11th May 2017)